NCT05541757View on ClinicalTrials.gov

Rivaroxaban - Percutaneous Coronary Intervention

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 1, 2022

Study Completion Date

March 1, 2022

Conditions
Coronary Artery DiseaseAtrial Fibrillation
Interventions
DRUG

In vitro heparin

In vitro heparin and in vitro LMWH

Trial Locations (1)

Unknown

Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Bursa

All Listed Sponsors
lead

Bursa Postgraduate Hospital

OTHER

NCT05541757 - Rivaroxaban - Percutaneous Coronary Intervention | Biotech Hunter | Biotech Hunter